Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer - Non Small Cell Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung EGFR Exon 19 Deletion Mutation Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–100 year

Sex eligibility

Female

Study type

Observational

Primary location

Our Lady of the Lake Regional Medical Center

Baton Rouge, Louisiana, 70808, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18-100 years old
Biologically born female
Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
No cancer diagnosis (Arm 2-health control)

Exclusion criteria

less than 18 years of age
Biologically born male
Incarcerated at the time of participation

Treatment and study plan

Blood Draw

Other

A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.

gene sequencing

Other

Subjects will have their DNA sequenced within and around the EGFR gene.

Primary outcomes

Differences in DNA sequence of EGFR gene

Time frame: From enrollment to end of data analysis at 6 months

Subjects who have EGFR positive lung cancer will have their gene sequence compared to those that are EGFR negative and do not have lung cancer to look for differences in the sequence.

Study contacts

Contact information is provided by the study sponsor or research team.

Christine LeBoeuf, DNP

CONTACT

[email protected]

225-763-5956

Cynthia Knox, MBA

CONTACT

[email protected]

225-765-3344

Sponsors and collaborators

Lead sponsor

Our Lady of the Lake Hospital

Other

Registry information

Acronym: EGFR Lung Canc

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Oct 26, 2024
Registry last updated: Mar 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting